Evidence map›Paper›PMID 38398070›Full record

ArticleBiomedicines2024

Design and Synthesis of Immunoadjuvant QS-21 Analogs and Their Biological Evaluation.

Wei Yuan, Ziming Wang, Yening Zou, Guojun Zheng

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wei YuanState Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Ziming WangState Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Yening ZouSinovac Life Sciences Co., Ltd., Beijing 102601, China.
Guojun ZhengState Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Beijing University of Chemical Technology · CNSinovac Biotech · CN

Funding

Beijing Natural Science Foundation No. L212001National Key R&D Program of China No. 2021YFC2101503, No. 2021YFC2102900
6 · The paper itself

Abstract

A series of novel immunoadjuvant QS-21 analogs were synthesized, and their effects on the in vitro hemolysis of red blood cells were evaluated using QS-21 as a control and hemolytic properties as an index. Our results show that all the QS-21 analogs had lower hemolytic effects than QS-21, and their concentrations exhibited a certain quantitative effect relationship with the hemolysis rate. Notably, saponin compounds

Indexed as

analoghemolyticQS-21synthesis

Identifiers

PMID38398070
PMCPMC10887094
OpenAlexW4391957083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.